Journal
JOURNAL OF NEPHROLOGY
Volume 32, Issue 2, Pages 307-314Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s40620-018-0557-4
Keywords
Fibroblast growth factor-23; End-stage renal disease; Continuous ambulatory peritoneal dialysis; Major adverse cardiac and cerebral event; Survival
Categories
Ask authors/readers for more resources
Background This study aimed to investigate the correlation of serum fibroblast growth factor-23 (FGF-23) level with clinical indexes, in particular to explore the value of FGF-23 in predicting major adverse cardiac and cerebral event (MACCE) risk in end-stage renal disease (ESRD) patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Methods In 270 ESRD patients undergoing CAPD consecutively enrolled in this prospective cohort study, we collected serum samples and performed enzyme-linked immunosorbent assay to detect FGF-23 expression. MACCE-free survival was defined as the date from enrollment to the date of MACCE occurrence. Results High levels of FGF-23 correlated with longer duration of dialysis (p = 0.002), elevated levels of calcium (p < 0.001), phosphorus (p = 0.037) and low density lipoprotein cholesterol (p = 0.027). MACCE occurrence rate was higher in the FGF-23 high-expression than low-expression group at 2 years (p = 0.028), 3 years (p = 0.001) and 4 years (p = 0.004). Kaplan-Meier curves revealed that MACCE-free survival was shorter in the FGF-23 high-expression than low-expression group (p = 0.004). Multivariate Cox's analysis showed that high FGF-23 expression (p = 0.011) as well as the duration of dialysis (p = 0.017), C-reactive protein (p = 0.011) and fasting blood glucose (p = 0.038) were independent predictive factors for reduced MACCE-free survival in ESRD patients undergoing CAPD. Conclusion High FGF-23 expression correlates with advanced disease conditions as well as increased MACCE risk, and is an independent factor predicting worse MACCE-free survival in ESRD patients undergoing CAPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available